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Background: In the treatment of multiple sclerosis (MS), the most important therapeutic aim of disease-modifying
treatments (DMTs) is to prevent or postpone long-term disability. Given the typically slow progression observed in
the majority of relapsing-remitting MS (RRMS) patients, the primary endpoint for most randomized clinical trials
(RCTs) is a reduction in relapse rate. It is widely assumed that reducing relapse rate will slow disability progression.
Similarly, MRI studies suggest that reducing T2 lesions will be associated with slowing long-term disability in MS.
The objective of this study was to evaluate the relationship between treatment effects on relapse rates and active
T2 lesions to differences in disease progression (as measured by the Expanded Disability Status Scale [EDSS]) in trials
evaluating patients with clinically isolated syndrome (CIS), RRMS, and secondary progressive MS (SPMS).
Methods: A systematic literature review was conducted in Medline, Embase, CENTRAL, and PsycINFO to identify
randomized trials published in English from January 1, 1993−June 3, 2013 evaluating DMTs in adult MS patients
using keywords for CIS, RRMS, and SPMS combined with keywords for relapse and recurrence. Eligible studies were
required to report outcomes of relapse and T2 lesion changes or disease progression in CIS, RRMS, or SPMS patients
receiving DMTs and have a follow-up duration of at least 22 months. Ultimately, 40 studies satisfied these criteria
for inclusion. Regression analyses were conducted on RCTs to relate differences between the effect of treatments
on relapse rates and on active T2 lesions to differences between the effects of treatments on disease progression
(as measured by EDSS).
Results: Regression analysis determined there is a substantive clinically and statistically significant association
between concurrent treatment effects in relapse rate and EDSS; p < 0.01. Lower treatment effects were associated
with higher relative rates of disease progression. Significant associations between T2 lesion measures and EDSS
measures also were found (p < 0.05), with some suggestion that the strength of the association may differ for older
versus newer DMTs.
Conclusions: Treatment differences in relapse reduction and T2 lesions are positively related to differences in
disease progression over the first two years of treatment.
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In the treatment of multiple sclerosis (MS), the most im-
portant therapeutic aim of disease-modifying treatments
(DMTs) is to prevent or postpone long-term disability,
typically defined by worsening on the Expanded Disability
Status Scale (EDSS) [1]. Given the normally slow progres-
sion observed in the majority of relapsing-remitting MS
patients (RRMS) [2], the primary endpoint for most ran-
domized clinical trials (RCTs) is a reduction in relapse
rate. It is widely assumed that reducing relapse rate will
slow disability progression [3]. Similarly, magnetic reson-
ance imaging (MRI) studies suggest that reducing T2 le-
sions [4], another short-term outcome in RCTs, will be
associated with slowing long-term disability in MS [5].
Sormani and colleagues performed a quantitative meta-
analysis of the predictive power of annualized relapse rates
and new/enlarged T2 lesions on EDSS progression across
a wide range of RCTs for RRMS [6]. Their results indi-
cated that the therapeutic benefit of the drugs, defined by
relapse rates and T2 lesions, generally correlated with
disability progression. The Sormani et al. study, however,
included an intercept in their regression analyses. Inclu-
sion of a non-zero intercept implies that two treatments
that do not differ in affecting the predictor (i.e., two treat-
ments that have the same relapse rate) will differ in affect-
ing the outcome (i.e., they will lead to different amounts
of EDSS progression). While it is conceptually possible for
some pairs of treatments, it would have to hold for all
pairs of treatments for the regression to be generalizable.
Furthermore, their analysis was limited to RCTs directed at
RRMS patients, thus restricting the conclusions that can
be drawn regarding the predictive relationship between re-
lapse rates and disability progression in other forms of MS.
In this quantitative meta-analysis, we have extended
the Sormani et al. analyses by including data from DMTs
involving secondary progressive MS (SPMS) patients. In
addition, we have expanded the MRI predictors to in-
clude T2 lesion volume, a potentially better predictor of
disability progression than new and enlarging T2 lesions.
Finally, our statistical approach, which excludes the use of
an intercept in the regression analyses, should provide a
more meaningful prediction of the relative risk of EDSS
progression from treatment differences in the surrogate
endpoints of interest (relapse rate and T2 lesions).
Methods
To identify and retrieve all potentially relevant trials asses-
sing treatment to delay or avoid relapse and disability pro-
gression in patients with RRMS, SPMS, and clinically
isolated syndrome (CIS), we conducted literature searches
in Medline (via PubMed), Embase, Cochrane Central
Register of Clinical Trials (CENTRAL), and PsycINFO. The
following algorithm was used in PubMed and analogous
searches were developed for the remaining databases:1. “Multiple Sclerosis, Relapsing-Remitting”[Mesh] OR
“Relapsing-Remitting Multiple Sclerosis” OR “sec-
ondary progressive multiple sclerosis” OR (“Multiple
Sclerosis”[Mesh] AND “secondary progressive”
[TIAB]) OR “clinically isolated syndrome” OR “early
MS” OR “early multiple sclerosis” OR “clinically def-
inite MS” OR “clinically definite multiple sclerosis”.
2. relapse OR relapses OR relapsed OR recurrence.
3. #1 AND #2.
Limits: Humans, English, clinical trial, Not reviews, edi-
torials, comments or case reports, and published between
January 1, 1993 and June 3, 2013, with an abstract.
Eligible studies included RCTs of at least 22 months’
duration assessing treatment of MS with DMTs that
reported both relapse and disability progression. The
Cochrane Library was also searched for recent system-
atic reviews of the subject, which could be used as a
source of further references. A manual check of refer-
ence lists from all included studies and relevant reviews/
meta-analyses was performed to supplement the above
searches and ensure a comprehensive review. Confer-
ence abstracts and unpublished literature were not
included.
Study selection
The full text articles of accepted abstracts that passed
the initial screening underwent review by investigators
trained in systematic review procedures and each ex-
cluded study required the consensus of an independent
investigator. Abstracts were included when all of the
following were true: the study was an RCT evaluating a
minimum of 20 adults with CIS, RRMS, or SPMS with at
least 22 months of follow-up in which relapse rate or MRI
lesion data and disability progression related to treatment
with DMTs (both approved and non-approved) were re-
ported, and the study was published within the search
period (January 1, 1993−June 3, 2013) for this review.
Data extraction
Data were collected into an electronic database devel-
oped specifically for this review by a single investigator
and independently verified by a second investigator. Dis-
crepancies in data extraction were reviewed by the two
investigators, and when necessary, any unresolved dis-
crepancies were resolved by a third investigator. The
endpoints sought for data capture included annualized
relapse rate (ARR), mean change in EDSS, the propor-
tion of patients with disability progression, as well as
counts and volume changes for T2 and gadolinium le-
sions. Definitions for relapse and disease progression
were also extracted as defined by authors to ensure simi-
lar methods were used in determining the presence of
these endpoints across studies.
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Regression analyses were conducted on RCTs to relate
differences between the effect of treatments on relapse
rates and on active T2 lesions, to differences between
the effects of treatments on disability progression, as
measured by EDSS.
The statistical methods used were similar to methods
outlined in meta-analyses conducted by Johnson et al.
[7] and Sormani et al. [6]. Specifically, weighted least-
squares regressions (in which the weight is the total
sample size of the two arms being compared) were con-
ducted for combinations of predictor and outcome listed
below. However, the analyses were not identical; unlike
Sormani et al. [6], we did not weight by duration of
follow-up and did not include an intercept in the regres-
sion analyses. As noted in the introduction, inclusion of a
non-zero intercept implies that two treatments with simi-
lar relapse rates could lead to a different degree of EDSS
progression. While this is conceptually possible for some
pairs of treatments, it would have to hold for all pairs of
treatments for the regression to be generalizable.
Regressions were conducted for the following combi-
nations of strata and predictor/outcome pairings:
Stratifications
 RRMS, limited to studies in which both arms have
approved DMTs (e.g., excluding studies with
alemtuzumab, statin-add-on, azathioprine-add-on,
cladribine tablets, MBP8298).
 All RRMS, all DMTs.
 SPMS/SPMS mixed.
Overall analyses across all disease courses (including
CIS) were also planned; however, given the important
clinical differences between disease stages with regard to
baseline rates of relapse, it was judged more appropriate
to analyze RRMS and SPMS studies independently. CIS
studies were not investigated independently, given the
sparseness of data available.
Regressions were conducted for the following combi-
nations of strata and predictor/outcome pairings:
Predictors/outcomes
 Ratio of ARR as a predictor of the relative risk of
EDSS progression (i.e., the ratio of the proportions
of patients with a predefined threshold of EDSS
increase).
 Ratio in number of new (or new/enlarged) T2
lesions as a predictor of the relative risk of EDSS
progression.
 Ratio of follow-up median T2 lesion volumes as a
predictor of the relative risk of EDSS progression.One other analysis was planned a priori; however, it
was not feasible due to sparseness of data:
 Ratio of gadolinium (GD) lesion volume as a
predictor of the relative risk of EDSS progression
(i.e., the ratio of the proportions of patients with a
predefined threshold of EDSS increase).
In cases where the relative risk of EDSS progression
was not available or calculable, the hazard ratio for time-
to-progression was used if it was available.
All calculations were performed using SAS® software
version 9.2 and SPSS® software version 15.0.
Results
A total of 1,104 unique citations were identified for re-
view at the abstract level. Of these, 91 abstracts were se-
lected for further review as full-text articles, and 1,013
were excluded. The primary reason for exclusion follow-
ing full text review was study duration less than
22 months (n = 23), followed by no extractable outcomes
of interest (n = 20). Figure 1 presents the study attrition
of the literature review. Forty primary articles [8-47] that
examined relapse rate and disability progression related
to treatment with DMTs in adults with CIS, RRMS, or
SPMS with at least 22 months of follow-up were identi-
fied for inclusion after full text review.
Of the 40 identified studies, the majority were on
RRMS populations (30), followed by SPMS (7). There
were only two CIS studies that met our inclusion cri-
teria, as well as one trial evaluating a mixed RRMS and
SPMS population.
In the figures representing the analyses (Figures 2, 3
and 4), each slope suggests a predicted difference between
any two treatments on an outcome (e.g., log-relative risk
of EDSS progression) given a difference between those
same treatments on a predictor (e.g., log-rate ratio of the
ARRs). The trial data contributing to the analyses are
provided in Tables 1 and 2. Evidence tables show the data
for the predictors (i.e., ARR ratio, final T2 lesion volume
ratio, ratio in number of new/enlarged T2 lesions) and
the outcome (ratio of patients with confirmed disease
progression).
Predicting disability progression from relapse
The relationships between the log-ARR and log-relative-
risk of EDSS progression were statistically significant across
all analyses (p < 0.001 for RRMS-all DMTs and RRMS-
approved DMTs, p = 0.027 for SPMS; see Table 3). The
strength of the predictive power of log-ARR to predict
EDSS progression did not vary substantively across ana-
lyses (slopes of 0.53, 0.50, and 0.40, respectively). Figure 2
plots the relationship between the log-ARR and log-
relative risk of EDSS progression for all RRMS studies.
Figure 1 Study attrition.
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for these two effects. For instance, the most rightward
point is from Gonsette et al. [23], which found almost
no difference in EDSS progression between the two arms
(approximately 18% for both) but a substantive differ-
ence in relapse rate (0.50 vs. 0.38, for a log-rate-ratio of
0.27). Each study with two arms (one treatment com-
parison, e.g., treatment A vs. treatment B) with sufficient
data contributed one data point to the analysis; studiesFigure 2 Predicting log-relative risk of EDSS from log-rate ratio of rel
Log RR.with three arms (two treatment comparisons, e.g., A vs.
B and A vs. C) contributed two data points.
Any given slope can be interpreted by determining
what difference between treatments in EDSS progression
one would expect given a realistic difference in ARR ra-
tio. A realistic difference in the ARR ratio can be opera-
tionalized as the median ARRR across all studies. In this
data, the median ratio of the mean relapse rate in the ac-
tive to the control group was 0.70. For instance, inapse rate: RRMS, all DMTs. EDSS: Expanded Disability Status Scale;
Figure 3 Predicting log-relative risk of EDSS from log-rate ratio of median T2 lesion volume: RRMS, all DMTs. EDSS: Expanded Disability
Status Scale.
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was 0.59, while it was 0.84 for placebo (relative risk
[RR] = 0.70).
As ln(0.70) = −0.353, the predicted log-relative-risk of
EDSS progression in studies like Johnson et al. is:
ln RREDSSð Þ ¼ Slope  ln ARRRð Þ;
Or
ln RREDSSð Þ ¼ 0:53 −0:353ð Þ;¼ −0:187:
As exp(−0.187) = 0.83, we can predict that the relative
risk of EDSS progression in studies like Johnson et al.Figure 4 Predicting log-relative risk of EDSS from log-rate ratio of act(i.e. with an ARRR of 0.70) will be 0.83. In Johnson
et al., the relative risk of EDSS progression was similar
to this value: it was 0.88 (21.6% progression in GA,
24.6% progression on placebo).
Predicting disability progression from lesion volume
The slope for predicting log-relative-risk of EDSS pro-
gression from the log-ratio of median follow-up in T2
volume (expressed as a percentage of baseline volume)
was statistically significant for the RRMS subset of stud-
ies (1.95, 95% CI [0.43, 3.48], p = 0.015) and marginally
statistically significant for the subset of RRMS studies on
approved DMTs (1.09, 95% CI [−0.09, 2.27], p = 0.067).ive T2 lesions count. EDSS: Expanded Disability Status Scale.
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36 Mitoxantrone 12 mg
vs. Placebo
124 0.35 1.02 0.343 8.00 22.00 0.364
Durelli L,
et al. [18]
24 IFNB-1a 30 μg vs. IFNB-
1b 250 μg


















120 0.73 1.05 0.695 17.50 16.80 1.042
Mikol DD,
et al. [32]
22 IFNB-1a vs. Glatiramer
acetate













130 0.22 0.59 0.373 16.00 25.00 0.640
O’Connor
P, et al. [34]
42 Glatiramer acetate vs.
IFNB-1b 250 μg
1,158 0.34 0.36 0.944 20.50 22.30 0.919
O’Connor
P, et al. [34]
42 Glatiramer acetate vs.
IFNB-1b 500 μg




24 IFNB-1b plus Inosine
vs. IFNB-1b
157 0.50 0.38 1.316 17.78 18.18 0.978
Coles AJ,
et al. [16]
36 Alemtuzumab vs. IFNB-
1a
333 0.1 0.36 0.278 9.00 26.20 0.344
Kappos L,
et al. [30]
24 Fingolimod 0.5 mg vs.
Placebo
843 0.18 0.40 0.450 17.70 24.10 0.734
Kappos L,
et al. [30]
24 Fingolimod 1.25 mg vs.
Placebo





942 0.23 0.73 0.315 17.00 29.00 0.586
Clanet M,
et al. [14]
36 IFNB-1a 30 μg vs. IFNB-
1a 60 μg
802 0.81 0.77 1.052 37.00 37.00 1.000
Ebers GC,
et al. [9]
104 IFNB-1a 22 μg vs.
Placebo
376 0.91 1.28 0.711 30.00 38.00 0.789
Ebers GC,
et al. [9]
104 IFNB-1a 44 μg vs.
Placebo




24 Glatiramer acetate vs.
Placebo









24 Hydrolytic enzymes vs.
Placebo





148 0.52 1.26 0.413 17.00 23.00 0.739
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51 0.445 1.31 0.340 7.00 37.00 0.189
Jacobs LD,
et al. [26]
24 IFNB-1a vs. Placebo 172 0.61 0.90 0.678 21.10 33.30 0.633
Ebers GC,
et al. [8]
36 IFNB-1b 1.6 MIU vs.
Placebo
228 1.05 1.21 0.868 28.00 28.00 1.000
Ebers GC,
et al. [8]
36 IFNB-1b 8 MIU vs.
Placebo







28 0.26 1.00 0.260 21.00 21.00 1.000
Andersen
O et al. [12]
36 IFNB-1a 22 μg vs.
Placebo
364 0.25 0.27 0.926 41.00 38.00 1.079
Cohen JA,
et al. [15]
24 IFNB-1a 60 μg vs.
Placebo
379 0.20 0.30 0.667 28.50 33.70 0.846
Panitch H,
et al. [35]
36 IFNB-1b 160 μg vs.
Placebo
622 0.20 0.28 0.714 39.00 34.00 1.147
Panitch H,
et al. [35]
36 IFNB-1b 250 μg vs.
Placebo
625 0.16 0.28 0.571 32.00 34.00 0.941
Kappos L,
et al. [28]
36 IFNB-1b vs. Placebo 718 0.44 0.64 0.688 38.90 49.70 0.783
Edan G,
et al. [41]
36 Mitoxantrone 12 mg/
m2 vs. IFNβ-1b 250 μg




24 MBP8298 vs. Placebo in
DR2+ and/or DR4+
haplotypes




24 MBP8298 vs. Placebo in
DR2- and/or DR4-
haplotypes
99 0.08 0.20 0.400 28.30 35.80 0.791
Comi G,
et al. [45]
24 Laquinimod 0.6 mg vs.
Placebo
1,106 0.30 0.39 0.769 11.10 15.70 0.707
Cohen JA,
et al. [43]
24 Alemtuzumab 12 mg
vs. IFNβ-1a 44 μg
563 0.18 0.39 0.462 8.00 11.12 0.719
Coles AJ,
et al. [44]
24 Alemtuzumab 12 mg
vs. IFNβ-1a 44 μg




240 mg BID vs.
Placebo




240 mg TID vs. Placebo
466 0.20 0.40 0.500 13.00 17.00 0.765
Fox RJ,
et al. [46]
24 Glatiramer acetate vs.
Placebo
471 0.29 0.40 0.725 16.00 17.00 0.941
ARR, annualized relapse rate; BID, twice daily; EDSS, Expanded Disability Status Scale; IFNB, Interferon-beta; μg, microgram; mg, milligram; mg/m2, milligrams per
square meter of body surface; MIU, million international units; TID, three times daily.
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analyses on SPMS patients; only one study [35] had such
data. Figure 3 plots the relationship between the log-rate
ratio of median T2 lesion volume and log-relative risk of
EDSS progression for all RRMS studies.
Following the example above, the median ratio of
follow-up T2 lesion volume was 0.96. For instance, in
Coles et al. 2008,[16] the median T2 lesion volume
dropped by 16.4% on alemtuzumab and dropped 13.3%
on placebo. This led to a ratio of 0.96 for the follow-up
values (0.836/0.867) and a log-ratio of −0.036.The predicted difference between treatments in EDSS
progression in studies like Coles 2008 [16] is:
ln RREDSSð Þ ¼ Slope  ln ratio of median T2 volumeð Þ;
Or
ln RREDSSð Þ ¼ 1:95  −0:036ð Þ ¼ −0:070
As exp(−0.070) = 0.93, we predict that the relative risk
of EDSS progression in studies like Coles et al. 2008 will
be 0.93. The actual ratio in Coles et al. 2008 was much









































24 IFNB-1b 250 μg vs.
Placebo
468 −10.60 −5.00 0.941 3.70 8.50 0.435 12.00 20.00 0.600
Comi G,
et al. [17]
24 IFNB-1a 22 μg vs.
Placebo
300 −13.00 8.80 0.800 2.00 3.00 0.667 15.00 20.00 0.750
Hartung HP,
et al. [24]
36 Mitoxantrone 12 mg
vs. Placebo



















93 14.50 30.30 0.879 17.50 16.80 1.042
Mikol DD,
et al. [32]
22 Glatiramer acetate vs.
IFNB-1a
585 0.82 0.67 1.224 8.70 11.70 0.744
Ravnborg




220 −1.06 1.21 0.978 5.20 8.00 0.650 25.00 28.50 0.877
Sorensen




110 2.70 3.50 0.771 16.00 25.00 0.640
O’Connor P,
et al. [34]
42 Glatiramer acetate vs.
IFNB-1b 250 μg
913 17.00 10.00 1.064 4.60 3.30 1.394 20.50 22.30 0.919
O’Connor P,
et al. [34]
42 Glatiramer acetate vs.
IFNB-1b 500 μg
971 17.00 12.00 1.045 4.60 3.30 1.394 20.50 22.30 0.919
Freedman
MS, et al. [21]
36 Placebo/IFNB-1a
44 μg vs. Placebo/
IFNB-1a 22 μg
53 -3.40 1.10 0.955 2.00 1.70 1.176 46.00 40.00 1.150
Freedman
MS, et al. [21]
36 Placebo/IFNB-1a
44 μg vs. IFNB-1a
22 μg
83 5.40 1.10 1.043 1.70 1.70 1.000 39.00 40.00 0.975
Freedman
MS, et al. [21]
36 Placebo/IFNB-1a
44 μg vs. IFNB-1a
22 μg























Table 2 Study summaries in trials reporting MRI changes and disability progression (Continued)
Kappos L,
et al. [30]
24 Fingolimod 0.5 mg vs.
Placebo
537 −1.69 8.61 0.905 2.50 9.80 0.255 17.70 24.10 0.734
Kappos L,
et al. [30]
24 Fingolimod 1.25 mg
vs. Placebo





942 1.90 11.00 0.173 17.00 29.00 0.586
Clanet M
et al. [14]
36 IFNB-1a 60 μg vs.
IFNB-1a 30 μg
386 −0.20 −1.29 1.011 8.00 9.00 0.889 37.00 37.00 1.000
Ebers GC,
et al. [9]
IFNB-1a 22 μg vs.
Placebo
279 −1.20 10.90 0.891 9.00 15.50 0.581 30.00 38.00 0.789
Ebers GC,
et al. [9]
IFNB-1a 44 μg vs.
Placebo
281 −3.80 10.90 0.867 5.50 15.50 0.355 26.50 38.00 0.697
Baumhackl
U, et al. [13]
24 Hydrolytic enzymes
vs. Placebo
291 −1.00 −1.00 1.000 28.00 26.00 1.077
Millefiorini
E, et al. [33]
24 Mitoxantrone vs.
Placebo
42 3.50 7.30 0.479 7.00 37.00 0.189
Giovannoni
G, et al. [22]
22 Cladribine 5.25 mg/kg
bw vs. Placebo
674 0.33 1.43 0.231 15.10 20.60 0.733
Giovannoni
G, et al. [22]
22 Cladribine 3.5 mg/kg
bw vs. Placebo
651 0.38 1.43 0.266 14.30 20.60 0.694
Jacobs LD,
et al. [26]
24 IFNB-1a vs. Placebo 164 −13.20 −6.50 0.928 21.10 33.30 0.633
Ebers GC,
et al. [8]
36 IFNB-1b 1.6 MIU vs.
Placebo
164 0.20 15.00 0.871 1.80 4.90 0.367 28.00 28.00 1.000
Ebers GC,
et al. [8]
36 IFNB-1b 8 MIU vs.
Placebo
167 −9.30 15.00 0.789 2.00 4.90 0.408 20.00 28.00 0.714
Panitch H,
et al. [35]
36 IFNB-1b 160 μg vs.
Placebo
81 0.80 10.90 0.909 39.00 34.00 1.147
Panitch H,
et al. [35]
36 IFNB-1b 250 μg vs.
Placebo
81 0.40 10.90 0.905 32.00 34.00 0.941
Edan G,
et al. [41]
36 Mitoxantrone 12 mg/
m2 vs. IFNβ-1b
250 μg
109 2.15 3.50 0.614 9.10 25.90 0.351
Freedman
MS, et al. [42]
24 MBP8298 vs. Placebo
in DR2+ and/or DR4+
haplotypes
513 0.90 6.20 0.95 3.90 3.30 1.182 30.70 27.80 1.104
Freedman
MS, et al. [42]
24 MBP8298 vs. Placebo
in DR2- and/or DR4-
haplotypes
99 16.10 0.70 1.15 3.20 3.30 0.970 28.30 35.80 0.791
Comi G,
et al. [45]
24 Laquinimod 0.6 mg
vs. Placebo


















Table 2 Study summaries in trials reporting MRI changes and disability progression (Continued)
Cohen JA,
et al. [43]
24 Alemtuzumab 12 mg
vs. IFNβ-1a 44 μg
563 −9.30 −6.50 0.97 8.00 11.12 0.719
Coles AJ,
et al. [44]
24 Alemtuzumab 12 mg
vs. IFNβ-1a 44 μg




240 mg BID vs.
Placebo




240 mg TID vs.
Placebo




240 mg BID vs.
Placebo




240 mg TID vs.
Placebo
466 4.70 17.40 0.270 13.00 17.00 0.765
Fox RJ,
et al. [46]
24 Glatiramer acetate vs.
Placebo
471 8.00 17.40 0.460 16.00 17.00 0.941
BID, twice daily; EDSS, Expanded Disability Status Scale; IFNB, Interferon-beta; μg, microgram; mg, milligram; mg/m2, milligrams per square meter of body surface; mg/kg bw, milligram per kilogram of body weight;


















Table 3 Results of the regression analysis
Model Predictor Slope p-value Lower 95% CI Upper 95% CI Adjusted R2
RRMS, All DMTs Annual relapse ratio log-ratio 0.531 < 0.001 0.425 9.637 0.750
RRMS, Approved DMTs Annual relapse ratio log-ratio 0.500 < 0.001 0.338 0.663 0.670
SPMS and SPMS Mixed Annual relapse ratio log-ratio 0.397 0.027 0.060 0.735 0.414
RRMS, All DMTs T2 median volume log-ratio 1.953 0.015 0.428 3.477 0.247
RRMS, Approved DMTs T2 median volume log-ratio 1.407 0.018 0.281 2.533 0.3305
RRMS, Not Approved T2 median volume log-ratio 3.978 0.151 −2.055 10.011 0.238
SPMS and SPMS Mixed T2 median volume log-ratio NA NA NA NA NA
RRMS, All DMTs T2 lesion count log-ratio 0.138 < 0.001 0.079 0.196 0.706
RRMS, Approved DMTs T2 lesion count log-ratio 0.162 0.025 0.027 0.298 0.467
SPMS and SPMS Mixed T2 lesion count log-ratio NA NA NA NA NA
DMT, disease-modifying treatment; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; NA, not available.
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http://www.biomedcentral.com/1471-2377/13/180lower: 0.34. This is perhaps unsurprising, given the wide
confidence interval for the slope (0.43–3.48); while we
see a significant relationship between median T2 per-
centage volume and EDSS progression, it is not one that
is precisely estimated.
Given the large difference in estimated slope between
RRMS, approved DMTs, and RRMS overall, sensitivity
analyses were conducted to explore the difference. A sep-
arate analysis was conducted limited to studies for which
the active treatment has not been approved. The relation-
ship between T2 lesion volume difference and the EDSS
relative risk was much stronger in the RRMS studies lack-
ing an approved DMT (slope = 3.98, 95% CI: –2.06–10.01)
but was not statistically significant (p = 0.15). The high
slope but wide confidence interval suggests that in these
studies, T2 lesion volume changes much less, relative to
change in EDSS progression, than in studies with ap-
proved DMTs. Specifically, there are sometimes small
differences in lesion volume even though there are large
differences in the percentage of patients with EDSS pro-
gression. This may be due to a different mechanism of
action, but also may simply be an artifact of sampling
error, given the wide confidence interval. If this signal is
not an artifact, it may suggest that newer and/or less con-
ventional therapies can affect lesion volume very little rela-
tive to their effect on short-term disease progression.
Prediction of EDSS progression using (log)-ratio of mean
number of active T2 lesions (RRMS, all DMTs, RRMS,
approved DMTs)
The slopes for the prediction of the log-relative-risk of
EDSS progression from the log-ratio of T2 lesions (gener-
ally defined as “new or enlarging” T2 lesions) were statisti-
cally significant (0.23 and 0.21 respectively, p < 0.001) for
both the set of all RRMS studies and the set restricted to
studies comparing approved DMTs. There were insuffi-
cient data on T2 lesion counts to conduct analyses on
SPMS patients.Following methods used previously, the median ratio
of follow-up T2 lesion volume was 0.48. For instance, in
Millefiorini et al. [33] the mean number of active T2 le-
sions was 7.3 in the placebo group and 3.5 in the mitox-
antrone group (3.5/7.3 = 0.48, log-ratio = −0.74).
The predicted difference between treatments in EDSS
progression in studies like Millefiorini et al. [33] is:
ln RREDSSð Þ ¼ 0:23  −0:74ð Þ ¼ −0:17
As exp(−0.17) = 0.84, we predict that the relative risk
of EDSS progression in studies like Millefiorini et al. will
be 0.84. The actual ratio in Millefiorini et al. was much
lower: 0.19; this study was an outlier, with only 7% of pa-
tients progressing on active treatment, while 37% pro-
gressed on placebo. However, the study had a very small
sample size of the study (42 patients with MRI data),
making it unsurprising that the predicted value is not
close to the study value. Figure 4 plots the relationship
between the log-rate ratio of active T2 lesion count and
log-relative risk of EDSS progression for all RRMS
studies.
Discussion
This literature review and analysis demonstrates signifi-
cant links between the therapeutic impact of DMTs on
EDSS progression and changes on surrogate markers of
disability, namely annualized relapse rates and T2 lesion
counts and volumes. This analysis improves upon the
Sormani et al. [6] analysis by including DMT studies of
SPMS, including RRMS studies published through June
of 2013, using revised data from the O’Connor et al. [34]
study, examining T2 lesion volume in addition to counts
of new and enlarging lesions, and exclusion of an intercept
in the regression analyses. Even though our methodo-
logical approach was different, we found substantively
similar results.
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pact of treating relapse on long-term disability progres-
sion, this analysis confirms that these relationships exist
over the short term (approximately two years) after
treatment initiation. We found a substantive clinically
and statistically significant link between concurrent
treatment effects in relapse rate and in EDSS. Specific-
ally, studies with lower relative differences in relapse rate
had lower relative differences in EDSS progression: the
stronger the treatment effect on reducing ARR, the
stronger the effect found for reducing disease progres-
sion. There was no conclusive evidence that the relation-
ships had different strengths between approved and
non-approved DMTs in RRMS patients or between types
of MS (RRMS and SPMS) patients, but the sparseness of
data and the presence of outliers in some analyses pro-
hibit strong generalizations. It remains possible that dif-
ferences in the mechanism of action between newer
DMTs and older DMTs may result in different relapse/
EDSS relationships. However, despite our review includ-
ing more than twice as many studies compared with
Sormani et al. (40 vs. 19), several of which evaluated
more recently approved DMTs such as dimethyl fumar-
ate, laquinimod, and fingolimod, the findings in the two
analyses are similar.
Significant association between T2 lesion measures and
EDSS measures were also found. Because not all studies
contributed data on all predictors and outcomes of inter-
est (e.g., not all studies reporting median T2 volume
change also reported the number of active T2 lesions, and
vice versa), it is difficult to make conclusions with regard
to what predictors and outcome pairs have the strongest
relationships. However, the values of adjusted-R2 were
higher and the relative confidence-interval widths were
narrower when the log-ratio of active T2 lesion counts
was the predictor of EDSS progression. It may be that the
wide variation present in T2 lesion volume blurs its rela-
tionship with disability progression. Our results suggest
that counting new and/or enlarged lesions is a better way
to predict concurrent disability progression than lesion
volume, but more research is needed to confirm this
supposition.
Since this analysis used only aggregated summary data
from published studies, we cannot necessarily assume
that any statistical association observed between group-
level variables may be translated to patient-level associa-
tions. Therefore, our findings cannot be used to predict
any outcome at the patient-level. In addition, unlike
some surrogate endpoint analyses [7], the relationships
in the current investigation are concurrent. Thus, even
though relationships were found between, for example,
ARR ratios and relative risk of EDSS progression, it does
not guarantee that early differences in relapse rate can
predict later differences in EDSS progression.Conclusions
While it remains possible that early relapses are con-
comitant with, rather than causative of, disease prog-
ression, treatment differences in relapse reduction are
significantly related to differences in disease progression
over the first two years of treatment. Similarly, treatment
differences in T2 lesion measures are also predictive of
treatment differences in relapse rates over the first two
years.
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